SMO and skin basal cell carcinoma: While Hh signaling has shown promise as a therapeutic target due to its dysregulated activation in various cancers, its clinical application has been limited by resistance to anti‐Hh agents.[49] Therefore, investigation of the underlying mechanisms responsible for cellular resistance to Hh inhibitors, particularly FDA‐approved Smo inhibitors like vismodegib and sonidegib for treating BCC,[50] may provide valuable insights into the regulation of Hh signaling.